This research study examines how a medication called lumateperone may affect mood symptoms, and inflammation in adults with bipolar disorder over approximately 6 weeks. An MRI scan to calculate biological age of the brain will also be obtained at the start of the study.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
25
Lumateperone 42 mg orally daily
Massachusetts General Hospital
Boston, Massachusetts, United States
RECRUITINGMADRS
Montgomery Asperg Depression Rating Scale
Time frame: 6 week
Inflammatory Markers
Tissue Necrosis factor alpha, C-reactive protein, Interleukins 1 beta, 6, 18
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.